future glp-1 drugs Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Patients Face New Barriers for
Description
Your gut houses a huge portion of your immune system
Phase 3 studies for type 2 diabetes are expected to begin no later than early 2019 and complete in late 2021
Pancreatitis was reported in 0.5% of Ozempic users and 0.8% of Saxenda users, compared to just 0.01% of those on Contrave
Nearly 808,000 people in the U.S
Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes
